{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-002988","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.958680+00:00","generated_at":"2026-06-18T09:48:54.942477+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Voyager reports Q4 2022 net loss of $23.6M; highlights partnerships with Neurocrine, Novartis, Pfizer","bullets":["Q4 2022 net loss $23.6M vs $5.7M income in Q4 2021; full-year net loss $46.4M vs $71.2M loss in 2021.","Neurocrine collaboration closed Jan 2023: $175M upfront, up to $4.2B milestones, plus royalties and opt-in for GBA1 program.","Novartis exercised capsid license options for two CNS targets (March 2023): $25M payment, up to $600M milestones plus royalties.","Pfizer exercised capsid option in Oct 2022: $10M payment, up to $290M milestones plus royalties.","Cash $118.8M at Dec 31, 2022; expected into 2025 after deals. Pipeline: VY-TAU01 selected, SOD1 candidate in H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-002988","json":"https://secwatch.observer/filing/0001558370-23-002988.json","markdown":"https://secwatch.observer/filing/0001558370-23-002988.md","text":"https://secwatch.observer/filing/0001558370-23-002988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000155837023002988/0001558370-23-002988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000155837023002988/vygr-20230307x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:48:54.942477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}